KEYNOTE-B15 ctDNA Analysis: Perioperative Enfortumab Vedotin + Pembrolizumab in Cisplatin-Eligible #MIBC. Presented by Jonathan Chatzkel, MD @MoffittNews. #ESMO26 written coverage

UroToday.com· @urotoday · X·2026-10-24 01:45· 2 days agoScore70

Body · original

KEYNOTE-B15 ctDNA Analysis: Perioperative Enfortumab Vedotin + Pembrolizumab in Cisplatin-Eligible #MIBC. Presented by Jonathan Chatzkel, MD @MoffittNews. #ESMO26 written coverage by @chavarriagaj @PSH_Urology > https://bit.ly/4Bv2fS3 #BladderCancer #PrecisionOncology @myESMO

401 views · 5 likes · 5 reposts · 1 reply

Conference abstracts

4734Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin

https://esmocongress.esmo.org

NCT04700124NCT04700124matched by - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

https://esmocongress.esmo.org

Replies in this thread

sciqst@sciqst
@urotoday @MoffittNews @chavarriagaj @PSH_Urology @myESMO For perioperative MIBC, the key question is whether ctDNA adds risk stratification beyond pathology; timing and assay thresholds will matter. Explore the broader evidence with a biomedical literature review at https://sciqst.com.

Source: UroToday.com · x.com